ReviewCancer immunology, immunotherapy : CII2007
Immunotherapy of renal cell carcinoma.
Review in Cancer immunology, immunotherapy : CII, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 66 citations in OpenAlex.
- Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions.Frontiers in immunology · 2025Review
- Chromophobe Renal Cell Carcinoma of a Renal Allograft.The American journal of case reports · 2021Article
- Present status and future perspective of peptide-based vaccine therapy for urological cancer.Cancer science · 2018Review
- Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma.Cancer immunology, immunotherapy : CII · 2017Article
- Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine.OncoTargets and therapy · 2016Article
- Brain metastasis in renal cancer patients: metastatic pattern, tumour-associated macrophages and chemokine/chemoreceptor expression.British journal of cancer · 2014Article
- Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes.Oncoimmunology · 2013Article
- Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.The Journal of biological chemistry · 2013Article
- Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma.Oncoimmunology · 2013Article
- Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2013Article
- How to detour Treg cells in T cell-based antitumor immune therapy.OncoTargets and therapy · 2013Article
- There is no place for targeted therapy neoadjuvant treatment in Polish Health System - An analysis of radical nephrectomies in patients with large kidney tumors.Central European journal of urology · 2013Article
- Peptide microarrays for the profiling of cytotoxic T-lymphocyte activity using minimum numbers of cells.Cancer immunology, immunotherapy : CII · 2010Article
- Immunologic mechanisms in RCC and allogeneic renal transplant rejection.Nature reviews. Urology · 2010Review
- Targeted therapies for renal cell carcinoma: understanding their impact on survival.Targeted oncology · 2010Review
- HLA ligand profiles of primary renal cell carcinoma maintained in metastases.Cancer immunology, immunotherapy : CII · 2009Article
- Vaccination strategies in patients with renal cell carcinoma.Cancer immunology, immunotherapy : CII · 2009Article
- Article
- The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines.Cancer immunology, immunotherapy : CII · 2009Article
- Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma.Proteomics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinomas of the kidney generally have a poor prognosis and respond minimally to classical radiotherapy or chemotherapy. Immunotherapy constitutes an interesting alternative to these established forms of treatment, and indeed, cytokine-based therapies have been used for many years, leading to favorable clinical responses in a small subset of patients. During the past few years, immunotherapeutical trials targeting renal cell tumor-associated antigens have also been reported, with diverse passive or active approaches using antibodies or aimed at activating tumor-directed T lymphocytes. The following review presents the results and the progress made in the field, including classical cytokine treatments, non-myeloablative stem cell transplantation and antigen specific-based trials, with special focus on T-cell studies. In consideration of the few specific molecular targets described so far for this tumor entity, current strategies which can lead to the identification of new relevant antigens will be discussed. Hopefully these will very soon contribute to an improvement in renal cell carcinoma specific immunotherapy and its evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.